The impact of patient preferences on the cost-effectiveness of intensive glucose control in older patients with new-onset diabetes.

No abstract is available for this paper.

• Publication year

  2006

• Venue

  Diabetes Care

• Publication date

  2006-02-01

• Fields of study

  Medicine, Economics

• Identifiers
  DOI 10.2337/DIACARE.29.02.06.DC05-1443PMID 16443870PMCID PMC2292131
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Economic Costs of Diabetes in the U.S. in 2007

  2008cited by this paper
• Implications of New Geriatric Diabetes Care Guidelines for the Assessment of Quality of Care in Older Patients

  2006cited by this paper
• Brief report: the burden of diabetes therapy: implications for the design of effective patient-centered treatment regimens.

  2005cited by this paper
• Standards of medical care in diabetes.

  2005cited by this paper
• [The care of the older person with diabetes mellitus].

  2005cited by this paper
• BRIEF REPORT: The burden of diabetes therapy

  2005cited by this paper
• Impact of Changes in HbA1c, Lipids and Blood Pressure on Long-term Outcomes in Type 2 Diabetes Patients: An Analysis Using the CORE Diabetes Model

  2004cited by this paper
• Standards of medical care in diabetes.

  2004cited by this paper
• The CORE Diabetes Model: Projecting Long-term Clinical Outcomes, Costs and Costeffectiveness of Interventions in Diabetes Mellitus (Types 1 and 2) to Support Clinical and Reimbursement Decision-making

  2004cited by this paper
• Guidelines for improving the care of the older person with diabetes mellitus.

  2003cited by this paper
• Economic costs of diabetes in the US in 2002.

  2003cited by this paper
• Glucose, Blood Pressure, and Lipid Control in Older People with and without Diabetes Mellitus: The Cardiovascular Health Study

  2002cited by this paper
• Cost-effectiveness of intensive glycemic control, intensified hypertension control, and serum cholesterol level reduction for type 2 diabetes.

  2002cited by this paper
• Estimating Utility Values for Health States of Type 2 Diabetic Patients Using the EQ-5D (UKPDS 62)

  2002cited by this paper
• Valuing health-related quality of life in diabetes.

  2002cited by this paper
• Health-related quality of life and treatment satisfaction in Dutch patients with type 2 diabetes.

  2002cited by this paper
• Preference-based measures in economic evaluation in health care.

  2000cited by this paper
• Quality of life in type 2 diabetic patients is affected by complications but not by intensive policies to improve blood glucose or blood pressure control (UKPDS 37). U.K. Prospective Diabetes Study Group.

  1999cited by this paper
• Glycemic control with diet, sulfonylurea, metformin, or insulin in patients with type 2 diabetes mellitus: progressive requirement for multiple therapies (UKPDS 49). UK Prospective Diabetes Study (UKPDS) Group.

  1999cited by this paper
• Glycemic Control with Diet, Sulfonylurea, Metformin, or Insulin in Patients with Type 2 Diabetes Mellitus: Progressive Requirement for Multiple Therapies (UKPDS 49)

  1999cited by this paper
• Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33)

  1998cited by this paper
• Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). UK Prospective Diabetes Study (UKPDS) Group.

  1998cited by this paper
• The epidemiology of cardiovascular disease in type 2 diabetes mellitus: how sweet it is ... or is it?

  1997cited by this paper
• Estimated Benefits of Glycemic Control in Microvascular Complications in Type 2 Diabetes

  1997cited by this paper
• Model of Complications of NIDDM: I. Model construction and assumptions

  1997cited by this paper
• Primer on Medical Decision Analysis: Part 3—Estimating Probabilities and Utilities

  1997cited by this paper
• Model of Complications of NIDDM: II. Analysis of the health benefits and cost-effectiveness of treating NIDDM with the goal of normoglycemia

  1997influential reference
• Panel on cost-effectiveness in health and medicine.

  1996cited by this paper
• The role of cost-effectiveness analysis in health and medicine. Panel on Cost-Effectiveness in Health and Medicine.

  1996cited by this paper
• Sociodemographic Characteristics of Persons with Diabetes

  1996cited by this paper
• Recommendations of the Panel on Cost-effectiveness in Health and Medicine.

  1996cited by this paper
• Magnetic resonance angiography in progressive renal failure: a technology assessment.

  1995cited by this paper
• Foot infections in diabetic patients. Decision and cost-effectiveness analyses.

  1995cited by this paper
• Economic impact of diabetes mellitus in the elderly.

  1990cited by this paper
• Non-insulin-dependent diabetes in older patients. Complications and risk factors.

  1986cited by this paper
• Target Population: Members of the DPP cohort 25 years of age or older with impaired glucose tolerance. Time Horizon: Lifetime. Perspectives: Health system and societal. Interventions: Intensive lifestyle, metformin, and placebo interventions

  year unknowncited by this paper

• A Review of Heterogeneity in Comparative Economic Analysis, with Specific Considerations for the Decentralized US Setting and Patient-Centered Care

  2025cites this paper
• The Impact of Underlying Conditions on Quality-of-Life Measurement Among Patients with Chronic Wounds, as Measured by Utility Values: A Review with an Additional Study

  2023cites this paper
• Expected Health Benefits of SGLT-2 Inhibitors and GLP-1 Receptor Agonists in Older Adults

  2023cites this paper
• Pharmacoeconomic evaluation of insulin aspart and glargine in type 1 and 2 diabetes mellitus in Iran

  2023cites this paper
• Incorporating prior beliefs into meta-analyses of health state utility values using the Bayesian Power Prior.

  2023cites this paper
• The individualisation of glycaemic targets in response to patient characteristics in type 2 diabetes: a scoping review.

  2022cites this paper
• Health state utilities associated with treatment process for oral and injectable GLP-1 receptor agonists for type 2 diabetes

  2021cites this paper
• Strategies to identify individuals with monogenic diabetes: results of an economic evaluation

  2020cites this paper
• Features of postoperative therapy in patients with type ІІ diabetes

  2020cites this paper
• Spices

  2020cites this paper
• Spices: Pharmacological and Anti-Diabetic Activities

  2020cites this paper
• Approaches to Risk Assessment Among Older Patients With Diabetes

  2019cites this paper
• Effects of Expanding Health Screening on Treatment - What Should We Expect? What Can We Learn?

  2018cites this paper
• Association of cognitive-emotional regulation strategies to depressive symptoms in type 2 diabetes patients

  2018cites this paper
• Providing cost‐effective diabetes care

  2017cites this paper
• Management of diabetes in older adults.

  2017cites this paper
• Individualized Glycemic Control for U.S. Adults With Type 2 Diabetes

  2017cites this paper
• Chasing the Missing Diagnoses: Exploring the Consequences of Removing Barriers to Information

  2017cites this paper
• Management of diabetes mellitus in older people with comorbidities

  2016cites this paper
• Chasing the Missing Diagnoses : Exploring the Unintended Consequences of Low-Cost Health Screenings

  2016cites this paper
• Older Adults' Perceived Challenges With Health Care Providers Treating Their Type 2 Diabetes and Comorbid Conditions

  2014cites this paper
• Challenges to time trade-off utility assessment methods: when should you consider alternative approaches?

  2014cites this paper
• Effect of patients' risks and preferences on health gains with plasma glucose level lowering in type 2 diabetes mellitus.

  2014cites this paper
• Utilities associated with subcutaneous injections and intravenous infusions for treatment of patients with bone metastases

  2013cites this paper
• Stratified Patient-Centered Care in Type 2 Diabetes

  2013cites this paper
• Cost-Effectiveness of MODY Genetic Testing: Translating Genomic Advances Into Practical Health Applications

  2013cites this paper
• Patient-centered medicine and patient-oriented research: improving health outcomes for individual patients

  2013cites this paper
• Age ≥ 60 years was an independent risk factor for diabetes-related complications despite good control of cardiovascular risk factors in patients with type 2 diabetes mellitus.

  2013cites this paper
• Baseline comparison of three health utility measures and the feeling thermometer among participants in the action to control cardiovascular risk in diabetes trial

  2012cites this paper
• An Economic Evaluation of Atorvastatin for Primary Prevention of Cardiovascular Events in Type 2 Diabetes

  2012cites this paper
• Estimated morbidity and mortality in adolescents and young adults diagnosed with Type 2 diabetes mellitus

  2012cites this paper
• A meta-analysis of health state valuations for people with diabetes: explaining the variation across methods and implications for economic evaluation

  2011cites this paper
• Simulation of Quality-Adjusted Survival in Chronic Diseases

  2011cites this paper
• Health Utilities for Children and Adults With Type 1 Diabetes

  2011cites this paper
• Preferences for type 2 diabetes health states among adolescents with or at risk of type 2 diabetes mellitus

  2011cites this paper
• Health state utility in patients with osteoarthritis of the hip and total hip arthroplasty.

  2011cites this paper
• Personalized Medicine and Genomics: Challenges and Opportunities in Assessing Effectiveness, Cost-Effectiveness, and Future Research Priorities

  2010cites this paper
• PDB2 THE IMPACT OF ORAL ANTIDIABETICS ON WEIGHT IN THE ELDERLY WITH TYPE 2 DIABETES MELLITUS IN THE AMBULATORY SETTING

  2010cites this paper
• Debateeconomics: the start of clinical freedom

  2010cites this paper
• Cost Effectiveness of Atorvastatin in Patients with Type 2 Diabetes Mellitus

  2010cites this paper
• Preferences of diabetes patients and physicians: A feasibility study to identify the key indicators for appraisal of health care values

  2010cites this paper
• Health economics: the start of clinical freedom

  2010cites this paper
• Patient preferences in the treatment of diabetic retinopathy

  2009cites this paper
• Ökonomische Evaluierung von Präventionsmaßnahmen zur Reduzierung von Spätkomplikationen des Typ-2 Diabetes in Österreich mittels Markov Monte-Carlo Simulation

  2008cites this paper
• Variation in Treatment Preferences and Care Goals Among Older Patients With Diabetes and Their Physicians

  2008cites this paper
• Approaches to Treatment of Type 2 Diabetes

  2008cites this paper
• Ethnic difference in patients with type 2 diabetes mellitus in inter-East Asian populations: a systematic review and meta-analysis focusing on fasting serum insulin.

  2008cites this paper
• The Effect of Comorbid Illness and Functional Status on the Expected Benefits of Intensive Glucose Control in Older Patients with Type 2 Diabetes: A Decision Analysis

  2008cites this paper
• Ethnic difference in inter-East Asian subjects with normal glucose tolerance and impaired glucose regulation: a systematic review and meta-analysis focusing on fasting serum insulin.

  2008cites this paper
• Perceptions of Quality‐of‐Life Effects of Treatments for Diabetes Mellitus in Vulnerable and Nonvulnerable Older Patients

  2008cites this paper
• Tamoxifen for Breast Cancer Risk Reduction: Impact of Alternative Approaches to Quality-of-Life Adjustment on Cost-Effectiveness Analysis

  2008cites this paper
• The cost-effectiveness of improving diabetes care in U.S. federally qualified community health centers.

  2007cites this paper
• Health and Quality of Life Outcomes

  2007cites this paper
• The Complexities of Comparative Effectiveness

  2007cites this paper
• Metabolic syndrome and its relationship with insulin resistance , endothelial dysfunction and atherogenesis

  2007cites this paper
• Measuring progress toward achieving hemoglobin A1c goals in diabetes care: pass/fail or partial credit.

  2007cites this paper
• Patient Perceptions of Quality of Life With Diabetes-Related Complications and Treatments

  2007cites this paper
• Quality Indicators for the Care of Diabetes Mellitus in Vulnerable Elders

  2007cites this paper
• COST ANALYSIS OF ANTIDIABETIC DRUGS FOR DIABETES MELLITUS OUTPATIENT IN KODYA YOGYAKARTA HOSPITAL

  2007cites this paper
• Proposition 71 and CIRM—assessing the return on investment

  2007cites this paper
• Cost-effectiveness and cost-utility of insulin glargine compared with NPH insulin based on a 10-year simulation of long-term complications with the Diabetes Mellitus Model in patients with type 2 diabetes in Switzerland.

  2007cites this paper
• Which health-related quality of life score? A comparison of alternative utility measures in patients with Type 2 diabetes in the ADVANCE trial

  2007cites this paper
• Using clinical guidelines designed for older adults with diabetes mellitus and complex health status.

  2006cites this paper
• Current literature in diabetes

  2006cites this paper
• O R I G I N a L I N V E S T I G a T I O N Open Access

  year unknowncites this paper